Randox

The Prostate Cancer Risk Score

Randox

Overview

The Randox Advanced PSA Test goes beyond the limitations of a standard PSA test by integrating a Prostate Cancer Risk Score. This advanced test utilises a novel combination of biomarkers, including PSA, to more accurately assess an individual’s risk of developing prostate cancer.



The Randox Prostate Cancer Risk Score

The Randox Prostate Cancer Risk Score incorporates a combination of four biomarkers — EGF, IL-8, MCP-1, and tPSA.

This innovative approach has been shown to significantly enhance the predictive accuracy of prostate cancer risk assessment compared to using PSA levels alone.

The test is supported by clinical studies, which have demonstrated its effectiveness in better stratifying patients into high and low-risk categories.


How the Test Works

1. Clinical & Demographic Data Collection: Patient information, including clinical history, is collected.

2. Serum Sample Analysis: The serum is analysed using Randox’s Biochip Array Technology, which evaluates the levels of the four key biomarkers.

3. AI-Driven Risk Stratification: The results are analysed using an AI algorithm to generate a personalised risk score, which categorises patients into low or high-risk groups for prostate cancer.

4. Actionable Insights:
  • High-Risk Patients: Referred for further investigation.
  • Low-Risk Patients: May be reassured and avoid unnecessary procedures, with the option for follow-up testing if needed.

Benefits of Using this Randox Test

Improved Accuracy

The Randox Prostate Cancer Risk Score improves the accuracy of prostate cancer detection by combining multiple biomarkers beyond just PSA. This advanced approach reduces false positives and helps distinguish between benign conditions and potential cancer, leading to more reliable results.

Reduced Unnecessary Procedures

By offering a more precise risk assessment, the Randox test significantly lowers the need for unnecessary invasive procedures like biopsies. Patients identified as low-risk can avoid the physical and emotional stress associated with these follow-up tests, reducing healthcare costs and improving patient experience.

Personalised Risk Assessment

The test provides a personalised risk score by analysing an individual’s specific biomarker levels along with their clinical and demographic data. This tailored approach enables healthcare providers to make more informed decisions about the next steps, ensuring that patients receive care that is appropriate for their unique risk profile.

Get your Randox test

The Randox Prostate Cancer Risk Score represents a significant advancement in prostate cancer testing, offering a more accurate, personalised, and less invasive approach to managing prostate cancer risk.


Download the Randox flyer for more information